GLUE stock news

GLUE stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.

See the full wire

12 wire items

2026-10-28 11:00:00 UTC#527982newconfirmedpress release

Monte Rosa Therapeutics announces Novartis initiated second Phase 2 study for MRT-6160 in psoriatic arthritis

yahooimportance 0.40trust 0.90Monte Rosa Therapeutics, Inc. +0.50Novartis AG +0.50MRT-6160 +0.50+1 entities

2026-10-05 11:32:12 UTC#412970newconfirmednews

HC Wainwright & Co. reiterates Buy rating on Monte Rosa Therapeutics with $25 price target

tradingviewimportance 0.30trust 0.60HC Wainwright & Co. +0.30Monte Rosa Therapeutics, Inc. +0.30

2026-10-01 12:39:56 UTC#398668updateconfirmednews

Monte Rosa Therapeutics to advance anti-inflammatory agent to mid-stage trials following positive Phase 1 data

seeking alphaimportance 0.40trust 0.70Monte Rosa Therapeutics, Inc. +0.50

2026-10-01 11:03:18 UTC#397870newconfirmednews

Monte Rosa Therapeutics reports positive Phase 1 GFORCE-1 results for MRT-8102 in ASCVD patients

reutersimportance 0.60trust 0.80Monte Rosa Therapeutics, Inc. +0.70MRT-8102 +0.70GFORCE-1 +0.60

2026-10-01 10:21:07 UTC#397642newconfirmednews

H.C. Wainwright initiates Monte Rosa Therapeutics at Buy with $25 price target

tradingviewimportance 0.40trust 0.70H.C. Wainwright & Co. +0.30Monte Rosa Therapeutics, Inc. +0.50Novartis AG +0.30+2 entities

2026-09-13 09:29:12 UTC#303374newconfirmednews

Novartis pays Monte Rosa $50M milestone following first patient dosing in Phase 2 trial of MRT-6160 for Sjögren's

yahooimportance 0.40trust 0.70Novartis AG +0.30Monte Rosa Therapeutics, Inc. +0.50MRT-6160 +0.40+1 entities

2026-09-08 11:03:01 UTC#280050newconfirmednews

Monte Rosa receives $50M milestone as Novartis initiates Phase 2 trial for MRT-6160 in Sjögren’s disease

tradingviewimportance 0.50trust 0.80Monte Rosa Therapeutics, Inc. +0.60Novartis AG +0.20MRT-6160 +0.50+1 entities

2026-08-25 12:41:00 UTC#217480newconfirmednews

Guggenheim maintains $28.00 price target on Monte Rosa Therapeutics (GLUE)

dow_jonesimportance 0.30trust 0.60Monte Rosa Therapeutics, Inc. 0Guggenheim Partners, LLC 0

2026-08-07 18:30:00 UTC#146840newconfirmednews

JPMorgan cuts Monte Rosa Therapeutics price target to $27.00 from $31.00

dow_jonesimportance 0.30trust 0.70Monte Rosa Therapeutics, Inc. -0.30JPMorgan Chase & Co. -0.20

2026-08-06 20:23:17 UTC#140209newconfirmednews

Monte Rosa Therapeutics average analyst price target lowered to $30.33, 94% upside implied

tradingviewimportance 0.30trust 0.70Monte Rosa Therapeutics, Inc. +0.20

2026-08-03 13:29:00 UTC#117041newconfirmednews

Wedbush maintains Outperform rating on Monte Rosa Therapeutics

dow_jonesimportance 0.30trust 0.70Monte Rosa Therapeutics, Inc. +0.20Wedbush Securities Inc. +0.20

2026-07-31 18:09:15 UTC#111264updateconfirmednews

Monte Rosa and BioAge shares decline as Novo Nordisk clinical trial failure weighs on biotech sector

seeking alphaimportance 0.40trust 0.70Monte Rosa Therapeutics, Inc. -0.50BioAge Labs, Inc. -0.50Novo Nordisk A/S -0.30